Asset
Tixestobart
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05435339 | phase1_2 | terminated | 2022-10-04 | 2024-05-24 | Genmab | A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy |
FDA applications (0)
This company has no applications containing this asset.